Please ensure Javascript is enabled for purposes of website accessibility

This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029

By Alex Carchidi – Sep 9, 2021 at 5:49AM

Key Points

  • Companies with regularly recurring revenue have an easier time posting consistent revenue growth.
  • Making products that are platforms for complex tasks is one way to build a recurring revenue base.
  • Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Doing business as usual will be more than enough to make this company a strong investment.

You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present? 

Intuitive Surgical (ISRG 4.48%) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.

A surgical technician prepares an operating room that's equipped with a robotic surgical suite.

Image source: Getty Images.

Big growth is more than feasible

Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.

In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.​

For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base. 

The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors. 

So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts. 

All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade. 

But will it make investors richer?

I'm of the view that Intuitive's stock will multiply in value well before 2029.

Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.

First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.

Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.

ISRG Revenue (Quarterly) Chart

ISRG Revenue (Quarterly) data by YCharts 

Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.

When's the right time to buy?

In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.

Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems. 

So, there isn't much to hold investors back from buying the stock today.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical Stock Quote
Intuitive Surgical
ISRG
$270.39 (4.48%) $11.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.